Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
Xing Li
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, United States
Tanja Nielsen
Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States; Doctoral Degrees and Habilitations, Department of Biology, Chemistry, and Pharmacy, Freie Universität Berlin, Berlin, Germany
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, United States
André Terzic
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, United States; Department of Molecular and Pharmacology and Experimental Therapeutics, Mayo Clinic, La Jolla, United States; Center for Regenerative Medicine, Mayo Clinic, Rochester, United States; Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, United States
Paul Grossfeld
University of California San Diego, Rady’s Hospital, San Diego, United States; Division of General Internal Medicine, Mayo Clinic, Rochester, United States
Karen Ocorr
Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
Timothy J Nelson
Department of Molecular and Pharmacology and Experimental Therapeutics, Mayo Clinic, La Jolla, United States; Center for Regenerative Medicine, Mayo Clinic, Rochester, United States; Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, United States
Timothy M Olson
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, United States; Department of Molecular and Pharmacology and Experimental Therapeutics, Mayo Clinic, La Jolla, United States; Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, United States
Alexandre R Colas
Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States
Congenital heart diseases (CHDs), including hypoplastic left heart syndrome (HLHS), are genetically complex and poorly understood. Here, a multidisciplinary platform was established to functionally evaluate novel CHD gene candidates, based on whole-genome and iPSC RNA sequencing of a HLHS family-trio. Filtering for rare variants and altered expression in proband iPSCs prioritized 10 candidates. siRNA/RNAi-mediated knockdown in healthy human iPSC-derived cardiomyocytes (hiPSC-CM) and in developing Drosophila and zebrafish hearts revealed that LDL receptor-related protein LRP2 is required for cardiomyocyte proliferation and differentiation. Consistent with hypoplastic heart defects, compared to parents the proband’s iPSC-CMs exhibited reduced proliferation. Interestingly, rare, predicted-damaging LRP2 variants were enriched in a HLHS cohort; however, understanding their contribution to HLHS requires further investigation. Collectively, we have established a multi-species high-throughput platform to rapidly evaluate candidate genes and their interactions during heart development, which are crucial first steps toward deciphering oligogenic underpinnings of CHDs, including hypoplastic left hearts.